Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB/II, Single Arm, Multi-center Study of Nivolumab in Combination With Eribulin in HER2 Negative Metastatic Breast Cancer Patients

NCT04061863 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT04061863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04061863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB/II, Single Arm, Multi-center Study of Nivolumab in Combination With Eribulin in HER2 Negative Metastatic Breast Cancer Patients
Lead sponsor
Seoul National University Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 1, 2019
Completion date
December 31, 2022
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer